Billionaire “Shark Tank” investor Mark Cuban is reportedly teaming up with President Trump to expand the TrumpRx drug-pricing platform to include generic medications.

Cuban was set to appear at a Monday afternoon White House announcement of the expansion — marking a pivot for one of the country’s most prominent Democratic-aligned business figures as President Donald Trump expands direct-to-consumer prescription-drug sales.

News of Cuban’s expected appearance was reported by Bloomberg News.

The move to add generic drugs to TrumpRx — which doesn’t sell medicine, but points consumers to websites that do — is part of a White House push to lower prescription-drug costs ahead of the midterm elections this fall.

Through his Mark Cuban Cost Plus Drug Company, Cuban sells mail-order medications directly to consumers. He’s one of the country’s most outspoken critics of opaque pharmaceutical pricing systems.

He was also a vocal critic of Trump’s during the 2024 presidential contest, when he endorsed Democratic candidate Kamala Harris.

“He’s fun to hang around. He’s got a great personality, he’s charismatic. But I think he was a lousy president before, I think he’ll be a worse president this time,” he said of Trump on Fox Business in October 2024.

The Post has sought comment from Cuban and the White House.

The administration has been touting its agreements with drugmakers to lower prices for government programs and offer medications directly to consumers as part of a broader healthcare affordability push.

TrumpRx, the federally run website launched earlier this year, advertises steep discounts on dozens of brand-name medications through “Most Favored Nation” pricing deals negotiated with pharmaceutical manufacturers.

The site, which initially listed 43 branded drugs, currently lists 87 products ranging from diabetes and weight-loss medications to fertility treatments, cancer drugs and respiratory inhalers.

It was not immediately known which generic drugs would be added to the platform.

Several of the currently available medications are advertised at discounts exceeding 80% off their original list prices.

Wegovy, a weight-loss medication, is listed at “starting at $149” compared with an original price of $1,349.02 — an 89% discount, according to the TrumpRx website.

Ozempic, a diabetes treatment that has become wildly popular for weight loss, too, is listed starting at $199 compared with a list price of $1,027.51.

The site advertises the fertility treatment Cetrotide at $22.50, down from $316.12, while diabetes drug Jentadueto is listed at $55 compared with a price of $525.08.

Other heavily discounted drugs include Mayzent for multiple sclerosis, listed as “starting at $42” instead of $623; Farxiga, listed at $35 instead of $377.82; and Amjevita, a Humira biosimilar, listed at $299 instead of $1,484.16.

The discounts are part of a White House-backed effort to pressure drugmakers into lowering prices for American consumers by tying domestic pricing more closely to rates charged overseas.

The platform has expanded as more pharmaceutical manufacturers signed agreements with the administration.

Boehringer Ingelheim added diabetes drugs Jentadueto and Jentadueto XR, as well as COPD inhaler Striverdi Respimat, to the platform.

Novartis agreed to provide access to Mayzent, leukemia treatment Rydapt and lung-cancer drug Tabrecta.

Amgen added migraine treatment Aimovig, cholesterol drug Repatha and Humira biosimilar Amjevita.

GSK added several inhalers including Incruse, Arnuity and Anoro Ellipta along with antiviral drug Relenza.

Cuban’s alignment with parts of the administration’s drug-pricing push highlights the unusual political coalitions emerging around prescription-drug costs.

The businessman, who has long described himself as an independent and libertarian-leaning centrist, publicly supported the past several Dem presidential candidates — from Barack Obama and Hillary Clinton to Joe Biden and Harris.

In recent years, Cuban has pushed for lower generic-drug costs, greater price transparency and reforms aimed at middlemen in the pharmaceutical supply chain.

The billionaire entrepreneur has argued that middlemen known as pharmacy benefit managers prefer higher prices because they profit off of the system.